Ontology highlight
ABSTRACT:
SUBMITTER: Van Swearingen AED
PROVIDER: S-EPMC6779035 | biostudies-literature | 2018 Oct
REPOSITORIES: biostudies-literature
Van Swearingen Amanda E D AED Siegel Marni B MB Deal Allison M AM Sambade Maria J MJ Hoyle Alan A Hayes D Neil DN Jo Heejoon H Little Paul P Dees Elizabeth Claire EC Muss Hyman H Jolly Trevor T Zagar Timothy M TM Patel Nirali N Miller C Ryan CR Parker Joel S JS Smith J Keith JK Fisher Julie J Shah Nikita N Nabell Lisle L Nanda Rita R Dillon Patrick P Abramson Vandana V Carey Lisa A LA Anders Carey K CK
Breast cancer research and treatment 20180625 3
<h4>Purpose</h4>HER2 + breast cancer (BC) is an aggressive subtype with high rates of brain metastases (BCBM). Two-thirds of HER2 + BCBM demonstrate activation of the PI3K/mTOR pathway driving resistance to anti-HER2 therapy. This phase II study evaluated everolimus (E), a brain-permeable mTOR inhibitor, trastuzumab (T), and vinorelbine (V) in patients with HER2 + BCBM.<h4>Patients and methods</h4>Eligible patients had progressive HER2 + BCBM. The primary endpoint was intracranial response rate ...[more]